Focused libraries of genetic packages

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Robert Charles Ladner patent solves the following problem:

It is now common practice in the art to prepare libraries of genetic packages that each display, display and express, or comprise a member of a different family of peptides, polypeptides or proteins and general display, display and express, or comprise at least a portion of amino acid differences in the family. In many common libraries, peptides, polypeptides or proteins associated with the antibody (eg, single chain Fv (scFv), Fv, Fab, whole antibodies or minibodies (ie, dimers consisting VH linked with VL)). Usually, they comprise one or more of the CDRs and framework regions of the heavy and light chains of human antibodies.

Our analysis of this patent is as follows:

Robert Charles Ladner’s patent US 8895475 B2 deals with Focused libraries of genetic packages.
Focus library vector or gene packages that display, display and express, or comprise a member of a different family of antibody peptide, polypeptides or proteins and collectively display, display and express, or covers at least one of the focuses difference in families. The library of elevation and in the manner that mimic that found in native human antibodies.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Chromatography ligand

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Ge Healthcare Bio-Sciences Ab patent solves the following problem:

The immune system is composed of many interdependent cell that collectively protect the body from bacterial, parasitic, fungal, viral infections and from the growth of tumor cells. The guards in the immune system are macrophages that continually roam the bloodstream of their host. When challenged by infection or immunization, macrophages respond by engulfing invaders marked with foreign molecules known as antigens. This event, mediated by helper T cells, sets a complex chain reaction that results in the stimulation of B-cells. These B-cells, in turn, a protein called antibodies, which bind to foreign invaders. The binding event between antibody and antigen marks the foreign invader for destruction by phagocytosis or activation of the complement system. A number of different classes of antibodies, also known as immunoglobulin, is, like IgA, IGD, IgE, IgG, and IgM. They race not only in their physiological roles but also in their structure. From a structural point of view, IgG antibody carefully studied, perhaps because of the dominant role they play in a mature immune response. Polyclonal antibody according to standard methods by immunization of an animal with the appropriate antigen. In response, the animals and the polyclonal antibody. However, for many purposes, it is desired to have a clone of an antibody, known as monoclonal antibody. Monoclonal antibodies (mAbs) produced by the hybrid or fused cells contain a fusion between a normal B-cell, only one antibody, into an abnormal myeloma tumor cell. The resulting hybrid, known as a hybridoma, is these days used in standard methods for the production of antibody.

Our analysis of this patent is as follows:

Ge Healthcare Bio-Sciences Ab’s patent US 8895710 B2 deals with Chromatography ligand.
The present invention relates to a chromatography ligand described by the following formula R1R2N (P3) R4R5 where R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain containing 0-4 carbon atoms; P3 is a hydrocarbon chain containing 1-3 carbon atoms; R4 is a hydrocarbon chain containing 1-5 carbon atoms; and R5 is OH or H. invention also includes a separation matrix; containing ligands described with a porous support, such as particles or a membrane. The ligand matrix according to the invention is useful for the purification of biomolecules or organic compounds, such as proteins, peptides, DNA etc. is an advantage to use according to the invention is the purification of the antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Cathepsin S inhibitors

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Dcb-Usa, Llc, , National Tsing Hua University, , National Health Research Institutes patent solves the following problem:

Cathepsin S (CTSS), a proteolytic enzyme, plays an important role in the major histocompatibility complex (MHC) class II antigen presentation way. In particular, this enzyme degrades invariant chain (an MHC class II chaperone) by his removal from the MHC class II peptide-binding cleft. This facilitates loading the antigenic amide compounds of MHC class II -dimers and subsequent transport to the cell surface complex to initiate MHC class II restricted CD4 + recognition T-cell. See Pierre and Mellman, Cell 1998, 93, 1135-1145. It found that CTSS involved in autoimmune and inflammatory diseases, such as asthma, allergies, atherosclerosis, emphysema, and rheumatoid arthritis.

Our analysis of this patent is as follows:

Dcb-Usa, Llc, , National Tsing Hua University, , National Health Research Institutes’s patent US 8895497 B2 deals with Cathepsin S inhibitors.
Cathepsin S inhibitor of formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune / inflammatory diseases.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

High affinity antibodies that neutralize Staphylococcus enterotoxin B

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Morphotek, Inc. patent solves the following problem:

Bioterrorism threat received a great deal of attention at present because of the ease of use of many of these deadly agents as well as accessibility to the most vulnerable people. There may be considerable economic and political ramifications that follow a bioterrorism attack, as seen in the attack anthrax-laden envelopes in Washington, DC and New York in 2001 that resulted in the dismantling the postal service and 18 deaths. Because of the threat from such agents, the Centers for Disease Control on a list of biological agents that can be weaponized, and the potential to cause large scale morbidity and mortality. These selected agents are classified into three groups (A, B, and C) based on their potential for wide dissemination of the civilian population. Category B agents considered moderately easy to spread and, if distributed to the civilian population, resulting in moderate morbidity and mortality. Among the list of Category B agents are Staphylococcal enterotoxin B (SEB) made the microorganism Staphylococcus aureus (Mantis, NJ (2005) Adv Drug Del Pin 57: 1424-39). SEB has the potential to cause disease in humans at relatively low doses, in particular when the route of administration occur through a mucosal surface. Typical routes of administration for SEB is through inhalation as an aerosol or by ingestion of SEB-laden food or water.

Our analysis of this patent is as follows:

Morphotek, Inc.’s patent US 8895704 B2 deals with High affinity antibodies that neutralize Staphylococcus enterotoxin B.
If there are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. Furthermore, nucleic acid encoding such antibodies, and cells expressing the antibody given. Also provides methods for treating diseases mediated by, and for the neutralization Staphylococcus enterotoxin B.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Chromatography matrices including novel Staphylococcus aureus protein A based ligands

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Emd Millipore Corporation patent solves the following problem:

Ligands used in affinity chromatography often yield a high selectivity for the target molecule, thus resulting in high yield, high purity and fast economic and purification of target molecules. Staphylooccus aureus Protein A-based reagents and chromatography matrices found a widespread use in the field of affinity chromatography for capture and purification of antibody, and Fe-containing proteins as well as the analytical-scale method of antibody detection because of its ability to bind IgG, without significantly affecting the affinity immunoglobulin antigen.

Our analysis of this patent is as follows:

Emd Millipore Corporation’s patent US 8895706 B2 deals with Chromatography matrices including novel Staphylococcus aureus protein A based ligands.
The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding protein, Staphylooccus aureus Protein A (SpA), as well as methods of using the same .

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Monkey homolog of human interferon omega

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Janssen Biotech, Inc. patent solves the following problem:

Type I interferon (IFN) (IFN, IFN, IFN, IFN, IFN) are a family of structurally related cytokines with antiviral, antitumor and immunomodulatory effects (Hardy et al Blood 97: 473, 2001; Cutrone and Langer J. Biol Chem 276 :. 17140, 2001. Type I interferon (IFN) high in some inflammatory diseases and blockade of interferon alpha (IFN) in particular hold promise in the treatment of a variety of very autoimmune diseases, such as human systemic lupus erythematosus (murder), or Primary Sjogren's Syndrome.

Our analysis of this patent is as follows:

Janssen Biotech, Inc.’s patent US 8895700 B2 deals with Monkey homolog of human interferon omega.
Cytokine IFN nucleic acid from the cynomolgus monkey are useful for the expression of IFN protein functional homologs of human IFN. The nucleic acid and protein that made it useful in screening and safety testing of IFN, the seed and attempt to IFN modulators and related activities.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for detecting human BPLP protein or a maturation product thereof

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Institut Pasteur patent solves the following problem:

In a genomic approach, an androgen-regulated gene, usually expressed in submandibular gland (SMG) and prostate of adult mice, recognized (Rosinski-Chupin et al., 1988 and European patent 0 394 424). gene encoding a protein precursor, submandibular rat1 protein (SMR1) giving rise to the three structurally related peptides that selectively matured from the first in vivo through the canal multibasic places a paired basic amino acid or enzyme (Rougeot et al., 1994).

Our analysis of this patent is as follows:

Institut Pasteur’s patent US 8895251 B2 deals with Method for detecting human BPLP protein or a maturation product thereof.
The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a case involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or any of its products maturation, by detecting or quantifying in a biological sample from a test subject, a BPLP protein or a maturation product thereof, and comparing the production BPLP protein or maturation products with the production of the same in a biological sample from a control subject.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

High electron mobility transistor and method of forming the same

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Taiwan Semiconductor Manufacturing Company, Ltd. patent solves the following problem:

In semiconductor technology, because of their characteristics, Group III-Group V (or III-V) semiconductor compounds used in the formation of various integrated circuit devices, such as high power field-effect transistors, high -as frequency transistors, or high electron mobility transistors (HEMTs). A HEMT is a field effect transistor using a junction between two materials with different gaps band (ie, a heterojunction) as the way instead of a blast region, as is generally the case for metal oxide semiconductor field effect transistors (MOSFETs). Contrary to the MOSFETs, HEMTs have a number of desirable properties including high electron mobility, the ability to transmit signals at high frequency, and others

Our analysis of this patent is as follows:

Taiwan Semiconductor Manufacturing Company, Ltd.’s patent US 8895992 B2 deals with High electron mobility transistor and method of forming the same.
A semiconductor structure includes a first III-V compound layer. The second III-V compound layer would first III-V compound layer and different from the first III-V compound layer composition. A carrier channel located between the first III-V compound layer and the second III-V compound layer. A source part and a drain part of the cast of the second III-V compound layer. A gate electrode that on the second III-V compound layer between the parts source and the drain part. A fluorine regions included in the second III-V compound layer under the gate electrode. A diffusion barrier layer that on the second III-V compound layer. A gate dielectric layer that over the second III-V compound layer. The gate dielectric layer has a fluorine of fluorine and region under at least a portion of the gate electrode.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Mask material conversion

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Micron Technology, Inc. patent solves the following problem:

This creation relates generally to integrated circuit fabrication and, particularly, to masking techniques.

Our analysis of this patent is as follows:

Micron Technology, Inc.’s patent US 8895232 B2 deals with Mask material conversion.
The dimensions of the mask pattern, such as tar-multiplied spacers, who controlled the controlled growth of the standards after they formed. A pattern in mandrels made overlying a semiconductor substrate. Spacers then formed on the sidewalls of the mandrels set by a blanket layer of material on the mandrels and preferentially removing the spacer material from horizontal surfaces. The mandrels are selectively removed, leaving a pattern of standing spacers. The spacers comprise a material, such as polysilicon and amorphous silicon, known to increase the size of the surface oxidized. The spacers are oxidized and grew into a desired width. The spacers then used as a mask to pattern underlying layers and the substrate. Worthwhile, because the spacers grown by oxidation, chasing thinner layers can be placed on the mandrels, allowing the deposition of conformal blanket layers and widening the process window for spacer formation.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods of leukemia cell detection

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The The Regents Of The University Of Colorado, A Body Corporate patent solves the following problem:

Leukemia is the most common childhood cancer, accounting for more than 3000 new diagnoses in the US each year. See the Cancer Statistics Branch NCI. Cancer event and Survival among Children and Adolescents: United States Prophets Program, 1975-1995, 1999. Over 90% of it is acute leukemias of lymphoid or myeloid origin.

Our analysis of this patent is as follows:

The Regents Of The University Of Colorado, A Body Corporate’s patent US 8894975 B2 deals with Methods of leukemia cell detection.
Procedures are given for, inter alia, determine the presence of leukemia cells in a subject, determine the changes or potential changes in the number of leukemia cells in the issues of the day, to determine if a tissue of a subject includes a plurality of cells in leukemia or a plural ancestor leukemia cells, and determine whether a leukemia therapy administered to a subject is able to decrease the number of leukemia cells in a tissue in the subject .

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.